Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Parsons

Showing results (841-850 of 865) with videos related to

Pageof 87
Sort By:
Nature Communications|May 24, 2025
Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classificationMaria Zanti, Denise G O'Mahony, Michael T Parsons, et al.
Human Mutation|February 21, 2018
The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicityMara Colombo, Irene Lòpez-Perolio, Huong D Meeks, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 11, 2021
The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variantInge M M Lakeman, Alexandra J van den Broek, Juliën A M Vos, et al.
JAMA Oncology|July 3, 2020
Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)Valentina Silvestri, Goska Leslie, Daniel R Barnes, et al.
Human Mutation|May 10, 2024
A likelihood ratio approach for utilizing case-control data in the clinical classification of rare sequence variants: application to <i>BRCA1</i> and <i>BRCA2</i>Maria Zanti, Denise G O'Mahony, Michael T Parsons, et al.
British Journal of Cancer|June 20, 2019
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriersFrank Qian, Matti A Rookus, Goska Leslie, et al.
Communications Biology|October 6, 2022
Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriersChristopher Hakkaart, John F Pearson, Louise Marquart, et al.
Journal of the National Cancer Institute|July 28, 2021
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk ScoresDaniel R Barnes, Valentina Silvestri, Goska Leslie, et al.
Cancer Research|July 29, 2018
A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer RiskYingchang Lu, Alicia Beeghly-Fadiel, Lang Wu, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 16, 2020
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variantsDaniel R Barnes, Matti A Rookus, Lesley McGuffog, et al.
Pageof 87

Showing results (841-850 of 865) with videos related to

Sort By:
Pageof 87
Nature Communications|May 24, 2025
Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classificationMaria Zanti, Denise G O'Mahony, Michael T Parsons, et al.
Human Mutation|February 21, 2018
The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicityMara Colombo, Irene Lòpez-Perolio, Huong D Meeks, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 11, 2021
The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variantInge M M Lakeman, Alexandra J van den Broek, Juliën A M Vos, et al.
JAMA Oncology|July 3, 2020
Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)Valentina Silvestri, Goska Leslie, Daniel R Barnes, et al.
Human Mutation|May 10, 2024
A likelihood ratio approach for utilizing case-control data in the clinical classification of rare sequence variants: application to <i>BRCA1</i> and <i>BRCA2</i>Maria Zanti, Denise G O'Mahony, Michael T Parsons, et al.
British Journal of Cancer|June 20, 2019
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriersFrank Qian, Matti A Rookus, Goska Leslie, et al.
Communications Biology|October 6, 2022
Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriersChristopher Hakkaart, John F Pearson, Louise Marquart, et al.
Journal of the National Cancer Institute|July 28, 2021
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk ScoresDaniel R Barnes, Valentina Silvestri, Goska Leslie, et al.
Cancer Research|July 29, 2018
A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer RiskYingchang Lu, Alicia Beeghly-Fadiel, Lang Wu, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 16, 2020
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variantsDaniel R Barnes, Matti A Rookus, Lesley McGuffog, et al.
Pageof 87